[Patient-derived microtumors : Potential for therapeutic response prediction-a case study]

Area of Science:

• Oncology
• Immunotherapy
• Personalized Medicine

Background:

• The need for personalized cancer therapy drives demand for functional platforms predicting individual patient drug response.
• Current predictive models often lack the speed and efficacy required for clinical application.
• Three-dimensional cell culture models offer promising avenues due to their ability to mimic tumor complexity and structure.

Observation:

• A novel test system utilizing patient-derived microtumors (PDMs) and autologous tumor-infiltrating lymphocytes (TILs) was developed.
• PDMs and TILs were established from a renal cell carcinoma metastasis and characterized via immunohistochemistry and multiplex FACS.
• The system assessed tumor-specific cytotoxicity of standard and investigational compounds against PDMs and TILs.

Findings:

• The cytotoxicity assay demonstrated a significant therapeutic response (p=0.0004) to a programmed cell death protein 1 (PD-1) inhibitor and lenvatinib.
• In vitro results from the PDM-TIL model showed a positive correlation with the patient's individual in vivo response to therapy.
• The study highlights the predictive capability of this novel preclinical model.

Implications:

• Patient-derived models like this have the potential to predict individual cancer therapy response.
• This approach could significantly aid in optimizing treatment decision-making for cancer patients.
• Further development of such models may accelerate the adoption of precision oncology strategies.